CD274 and non-small cell lung carcinoma: Based on new data from clinical trials in NSCLC, immunotherapies form a new standard in 2 L treatment (nivolumab, pembrolizumab) [23, 24], or 1 L treatment (pembrolizumab) [25] of patients expressing PD-L1, and possibly even for those who do not.